[go: up one dir, main page]

PL336205A1 - Method of treating and preventing prostatic carcinoma as well as benign prostatic hypertrophy using selective modulators of oestrogen receptors - Google Patents

Method of treating and preventing prostatic carcinoma as well as benign prostatic hypertrophy using selective modulators of oestrogen receptors

Info

Publication number
PL336205A1
PL336205A1 PL98336205A PL33620598A PL336205A1 PL 336205 A1 PL336205 A1 PL 336205A1 PL 98336205 A PL98336205 A PL 98336205A PL 33620598 A PL33620598 A PL 33620598A PL 336205 A1 PL336205 A1 PL 336205A1
Authority
PL
Poland
Prior art keywords
treating
well
preventing
selective modulators
oestrogen receptors
Prior art date
Application number
PL98336205A
Other languages
English (en)
Inventor
Blake Lee Neubauer
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL336205A1 publication Critical patent/PL336205A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
PL98336205A 1997-04-09 1998-04-07 Method of treating and preventing prostatic carcinoma as well as benign prostatic hypertrophy using selective modulators of oestrogen receptors PL336205A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4322397P 1997-04-09 1997-04-09
PCT/US1998/007274 WO1998045288A1 (en) 1997-04-09 1998-04-07 Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogen receptor modulators

Publications (1)

Publication Number Publication Date
PL336205A1 true PL336205A1 (en) 2000-06-05

Family

ID=21926126

Family Applications (1)

Application Number Title Priority Date Filing Date
PL98336205A PL336205A1 (en) 1997-04-09 1998-04-07 Method of treating and preventing prostatic carcinoma as well as benign prostatic hypertrophy using selective modulators of oestrogen receptors

Country Status (16)

Country Link
EP (1) EP0975629A4 (no)
JP (1) JP2001518900A (no)
KR (1) KR20010006218A (no)
CN (1) CN1259944A (no)
AU (1) AU6966198A (no)
BR (1) BR9808515A (no)
CA (1) CA2286204A1 (no)
EA (1) EA199900914A1 (no)
HU (1) HUP0003589A3 (no)
ID (1) ID24358A (no)
IL (1) IL132277A0 (no)
NO (1) NO994903L (no)
PL (1) PL336205A1 (no)
TR (1) TR199902701T2 (no)
WO (1) WO1998045288A1 (no)
ZA (1) ZA982819B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6610706B1 (en) 1999-07-29 2003-08-26 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
US6653479B1 (en) 1999-07-29 2003-11-25 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride
WO2002089801A1 (en) * 2001-05-10 2002-11-14 Cedars Sinai Medical Center Use of benzothiophenes to treat and prevent prostave cancer
US7425565B2 (en) * 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
RU2261716C1 (ru) * 2004-02-24 2005-10-10 Долженков Сергей Дмитриевич Способ профилактики гнойно-воспалительных осложнений у больных доброкачественной гиперплазией простаты в послеоперационном периоде
EP2029128B1 (en) * 2006-05-22 2015-08-05 Hormos Medical Ltd. Method of treatment of chronic nonbacterial prostatitis with selective estrogen receptor modulators or aromatase inhibitors
CN102940619A (zh) 2007-10-16 2013-02-27 利普生物药剂公司 用于治疗代谢综合征的珠氯米芬
AU2013225869B2 (en) 2012-02-29 2017-06-08 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
EP3360870A1 (en) 2013-02-19 2018-08-15 Novartis AG Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
JP7048505B2 (ja) 2015-11-10 2022-04-05 パラクリン セラピューティクス エービー Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429922A (en) * 1988-03-09 1995-07-04 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for distinguishing virulent and non-virulent toxoplasma infections
ES2163587T3 (es) * 1995-02-28 2002-02-01 Lilly Co Eli Compuestos de benzotiofeno, productos intermedios, composiciones y procedimientos.
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US5731342A (en) * 1996-02-22 1998-03-24 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods

Also Published As

Publication number Publication date
HUP0003589A3 (en) 2002-02-28
WO1998045288A1 (en) 1998-10-15
NO994903D0 (no) 1999-10-08
NO994903L (no) 1999-12-09
IL132277A0 (en) 2001-03-19
AU6966198A (en) 1998-10-30
CN1259944A (zh) 2000-07-12
ID24358A (id) 2000-07-13
ZA982819B (en) 1999-10-04
HUP0003589A2 (hu) 2002-01-28
JP2001518900A (ja) 2001-10-16
TR199902701T2 (xx) 2000-02-21
EP0975629A1 (en) 2000-02-02
EA199900914A1 (ru) 2000-04-24
BR9808515A (pt) 2001-06-19
KR20010006218A (ko) 2001-01-26
CA2286204A1 (en) 1998-10-15
EP0975629A4 (en) 2001-03-21

Similar Documents

Publication Publication Date Title
GB2328348B (en) Closeable communication device and method of operating the same
HUP0003968A3 (en) Method of operating telecommunication network and device
GB2330585B (en) Gelling agent for hydrocarbon liquid and method of use
AU6393896A (en) Method for treating benign prostatic hyperplasia with thermal therapy
DK0925069T3 (da) Anvendelse af Cetrorelix til behandling af godartet prostatahypertrofi og prostatacancer
PL336205A1 (en) Method of treating and preventing prostatic carcinoma as well as benign prostatic hypertrophy using selective modulators of oestrogen receptors
ZA952763B (en) Use of alpha-1C specific compounds to treat benign prostatic hyperplasia
ZA981600B (en) Methods and compositions for treating stickies
GB9814178D0 (en) Gelling agent for hydrocarbon liquid and method of use
PL343413A1 (en) Communication device and method of operation
HUP0000192A3 (en) Compositions for treating soils, method of preparation and use thereof
PL335891A1 (en) Methods of and compositions for treating ovarian carcinoma
PL337358A1 (en) Catalytic composition, method of obtaining same and method of desulphurising mixtures of hydrocarbons
AU9128998A (en) Composition and method for the treatment of benign prostatic hyperplasia and prostatitis
EP0633781A4 (en) COMPOSITIONS AND METHODS FOR TREATING BENIGN PROSTATIC HYPERTROPHY.
PL336206A1 (en) Method of preventing mammary carcinoma by means of selective modulators of oestrogen receptors
GB2357792B (en) Method of injecting water and gas
PL342357A1 (en) Phtalimidoaarylopiperazines as antagonists of alpha receptor 1a useful in treatment useful in treating benign prostatic hypertrophy
GB2323257B (en) Frequency modulation method and modem unit employing such method
PL324172A1 (en) Malatonin agonists for treating mild forms of prostatic hypertrophy
GB0212982D0 (en) Closeable communication device and method of operating the same
EP1435913A4 (en) METHOD OF TREATING BENIGN PROSTATIC HYPERPLASIA AND OTHER BENCH PROSTATIC PATHOLOGIES
GB2358818B (en) Switchable spray generator and method of operation
AU6060299A (en) Method of treating hair loss using ketoamides
SI0925069T1 (sl) Uporaba Cetrorelix-a za zdravljenje benigne hipertrofije prostate in prostatnega raka